Wireless industry investors are likely transfixed by Sprint Nextel's (NYSE: S ) current limbo regarding acquisitions and suitors. Beyond overt headlines, Sprint has a covert secret that makes its business more interesting for the long term -- and even transformative for the wireless industry at large. Given this factor, I wish I could put Sprint on the watchlist for the real-money Prosocial Portfolio I'm managing for Fool.com.
However, I am paying attention to this stock, but I just can't buy. Here's why.
Headline drama
Who will acquire Sprint has been making major headlines this week. Japan's SoftBank made a $20.1 billion offer for the wireless company, but DISH Network (NASDAQ: DISH ) made an unsolicited $25.5 billion offer.
DISH has criticized the SoftBank deal, floating the argument that if the Japanese company buys Sprint, it could open the U.S. up to security issues, such as Chinese cyberattacks.
Regardless, this week a U.S. security committee cleared the SoftBank deal despite the hysteria. Meanwhile, Clearwire (NASDAQ: CLWR ) , a provider of 4G services, has postponed its shareholder vote regarding Sprint's overture to buy its remaining stake for $3.40 per share, citing DISH Networks' bid to buy it for $4.40 per share.
Top 10 Japanese Stocks To Watch Right Now: CSP Inc.(CSPI)
CSP Inc. engages in the development and marketing of information technology (IT) integration solutions and high-performance cluster computer systems to industrial, commercial, and defense customers worldwide. The company operates in two segments: Systems, and Service and System Integration. The Systems segment designs and manufactures specialty, high-performance computer signal processing systems for the aerospace and defense markets. These systems are used on land, and in airborne and shipboard platforms for high-speed digital signal processing in radar, sonar, and surveillance applications. The Service and System Integration segment consists of the computer maintenance and integration services, and third-party computer hardware and software value added reseller businesses. It also provides professional IT consulting services, including maintenance and technical support; implementation, integration, configuration, and installation services; enterprise security intrusion p revention, network access control, and unified threat management services; IT security compliance services; custom software applications and solutions development and support; and monitoring, reporting, and management of alerts for the resolution and preventive general IT and IT security support tasks. This segment offers its solutions and services for IT environments, including storage and servers, unified communications solutions, IT security solutions, and consulting services. The company markets its products and services through direct sales force, distributors, and resellers. CSP Inc. was founded in 1968 and is headquartered in Billerica, Massachusetts.
Advisors' Opinion:- [By Laura Brodbeck]
Tuesday
Earnings Expected From: Jabil Circuit, Inc. (NASDAQ: CSPI), Verifone Systems, Inc. (NYSE: PAY) Economic Releases Expected: Japanese trade balance, New Zealand current account, US current account, US CPIWednesday
Top 10 Japanese Stocks To Watch Right Now: ChinaCache International Holdings Ltd.(CCIH)
ChinaCache International Holdings Ltd. provides Internet content and application delivery services to businesses, government agencies, and enterprises in China. It offers Web Page Content Services to website operators; file transfer services; rich media streaming services that enable live streaming of media files; guaranteed application services for websites that incorporate applications with features, such as on-line booking and ordering, real-time stock quotes, and on-line surveys; managed internet data services; ChinaCache cloud services; and content bridging services. The company also provides various value-added services, such as geo-content acceleration services, performance evaluation module, scalable services routing services, link anti-hijack services, NetStorage services, user behavior analysis services, and Website performance evaluation services. The company was founded in 1998 and is headquartered in Beijing, the People?s Republic of China.
Advisors' Opinion:- [By Garrett Cook]
Technology shares fell around 0.27 percent in Thursday’s trading. Top decliners in the sector included TechTarget (NASDAQ: TTGT), down 5.3 percent, and ChinaCache International Holdings (NASDAQ: CCIH), off 2.11 percent.
- [By Eric Volkman]
ChinaCache International Holdings (NASDAQ: CCIH ) wants to spend money on its own shares after all. The company announced that its board has authorized a resumption of its stalled $10 million American Depositary Shares buyback program. It has plenty left in the tank. When halted, ChinaCache had spent only $1.5 million on such purposes.
5 Best Electric Utility Stocks To Buy Right Now: Pain Therapeutics Inc (PTIE)
Pain Therapeutics, Inc., incorporated in May 1998, is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. The Company�� lead drug candidate is REMOXY, which is a painkiller. It has collaboration agreement with King Pharmaceuticals, Inc. (King) develops and commercializes REMOXY and other opioid painkillers. The Company and King jointly managed a Phase III clinical program and New Drug Application (NDA) submission for REMOXY. It is also developing a pipeline of drug candidates in the area of oncology and hematology. It owns all commercial rights to its pipeline of drug candidates in oncology and hematology. As of December 31, 2010, the Company leased approximately 30,700 square feet of space in San Mateo, California and all of its operations are located in San Mateo.
REMOXY
REMOXY is a controlled-release oral capsule form of oxycodone in a highly viscous liquid formulation matrix that includes excipients. It is formulated to help address issues of abuse and misuse of time-release oxycodone tablets. REMOXY�� capsule dosage form provides therapeutic drug levels of oxycodone on a twice-daily dosing schedule, while resisting the rapid increases in plasma levels of oxycodone associated with common methods of abuse and misuse. Its formulation also resists delivery by unapproved routes of administration, such as injection, snorting or inhalation.
Metastatic Melanoma
The Company is developing a drug candidate called PTI-188 to treat metastatic melanoma, a form of skin cancer. PTI-188 is a monoclonal antibody linked to a radioisotope, intended to deliver doses of radiation lethal to melanoma tumors without harming normal tissue. In March 2010, the Company announced data from two open-label! , dose-escalating Phase I studies conducted in Israel to assess the safety, pharmacokinetics, dosimetry and anti-tumor activity of PTI-188. During the year ended December 31, 2010, the second study was completed. The technology used in this program was developed at the Albert Einstein College of Medicine (AECOM). It had licensed worldwide commercial rights to this technology from AECOM.
Hemophilia
The Company has a gene transfer program, initially developed at Stanford University, focused at correcting a genetic disorder in which patients are unable to stop bleeding. During 2010, it conducted a variety of pre-clinical studies with this technology. The Company has licensed worldwide commercial rights to the technology used in this program from Poetic Genetics, LLC (Poetic).
Other product candidates
The Company�� alliance with King includes development of three other abuse-resistant opioid product candidates: hydromorphone, hydrocodone and oxymorphone. Its abuse-resistant formulations of hydromorphone and hydrocodone have completed Phase I clinical trials. In January 2011, the Company announced that the Food and Drug Administration (FDA) had accepted its investigational IND, for abuse-resistant oxymorphone.
The Company competes with Roxane Laboratories, Purdue Pharma, King Pharmaceuticals, Inc., Abbott Laboratories, Cephalon, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals.
Advisors' Opinion:- [By Jessica Alling]
Elsewhere, Pfizer is evaluating its continued partnership on an experimental oxycodone capsule, Remoxy. The drug is an extended-release formula that is targeted at reducing abuse of the painkiller. After years of setbacks and postponements for FDA approval, Pfizer is weighing its options. Its partners for the drug, Pain Therapeutics (NASDAQ: PTIE ) and Durect, have both fallen heavily due to the news, with Pain Therapeutics falling more than 50% -- its largest decline ever.
- [By Sean Williams]
However, all isn't well when it comes to the future of abuse-resistant painkiller Remoxy, which was developed by Pain Therapeutics (NASDAQ: PTIE ) , using Durect's�special technology-based gel capsule to prevent abuse, and is licensed by Pfizer (NYSE: PFE ) . Remoxy has been rejected twice by the FDA -- the most recent coming in mid-2011 -- and Pfizer commented this morning that if it were to seek reapproval for the drug it wouldn't be for at least two more years. Given Pfizer's extensive product pipeline, losing Remoxy wouldn't be a big deal. For micro-cap clinical-stage companies like Pain Therapeutics and Durect, it'd be a gigantic blow. Fittingly, Pain Therapeutics and Durect shares imploded by 50% and 34%, respectively, on Friday.
Top 10 Japanese Stocks To Watch Right Now: Pacer International Inc.(PACR)
Pacer International, Inc., together with its subsidiaries, provides asset-light transportation and logistics services primarily in North America, Asia, Europe, Australia, South America, and Africa. It operates in two segments, Intermodal and Logistics. The Intermodal segment offers intermodal rail transportation, local cartage and trucking, intermodal marketing services, container capacity, on-site operational services, and door-to-door shipment management services. As of December 31, 2011, its equipment fleet consisted of 1,592 double-stack railcars, 18,183 containers, and 12,783 chassis. The Logistics segment provides highway brokerage, warehousing and distribution, international freight forwarding, ocean and air shipping, and supply chain management services, as well as offers non-vessel-operating common carrier to end-user customers. The company markets and supports its services to cargo owners, steamship lines, truckload carriers, truck brokers, and freight forwarders , as well as other third party transportation service providers, such as intermodal marketing companies, third-party logistics companies, and shippers? agents through its direct sales and customer service representatives. Pacer International, Inc. was founded in 1974 and is headquartered in Dublin, Ohio.
Advisors' Opinion:- [By Jake L'Ecuyer]
XPO Logistics (NYSE: XPO) shot up 7.06 percent to $30.01 after the company announced its plans to acquire Pacer International (NASDAQ: PACR) in a deal valued at $335 million.
- [By Vera Yuan]
Pacer International, Inc. (PACR) was acquired by XPO Logistics, Inc. which remains in our portfolio. We eliminated our position in specialty pharmaceutical company Actavis PLC (ACT) as the price to intrinsic value relationship narrowed. We originally received shares when Actavis bought portfolio holding Warner Chilcott. We eliminated our position in convenience store distributor Core- Mark Holding Co., Inc.( CORE) as the stock rose almost 40% over the last year and reached our estimate of intrinsic value.
Top 10 Japanese Stocks To Watch Right Now: Cellular Dynamics International Inc (ICEL)
Cellular Dynamics International, Inc., incorporated on November 16, 2007, develops and manufactures fully functioning human cells in industrial quantities to precise specifications. The Company�� iCell Operating System (iCell O/S) includes true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). Customers use its iCell O/S products, among other purposes, for drug discovery and screening; to test the safety and efficacy of their small molecule and biologic drug candidates; for stem cell banking; and in researching cellular therapeutics. The Company�� iCell product line includes four different cell types: cardiomyocytes, neurons, hepatocytes and endothelial cells. The Company is actively developing an additional seven different cell types. iCell products are a consumable designed to be used once and then reordered.
The Company manufactures its iCell products from its iPSCs. An iPSC is a cell that has the ability both to replicate indefinitely and to be transformed into any cell type in the human body. The Company�� iCell O/S consists of six products, which include iCell Cardiomyocytes, iCell Neurons, iCell Endothelial Cells, iCell Hepatocytes and MyCell.
Advisors' Opinion:- [By John Udovich]
Stem cells may not be in the news much�as the sector has moved beyond the use of embryotic�ones, but small cap stem cell stocks Cellular Dynamics International Inc (NASDAQ: ICEL), International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX) have been fairly active over the past several trading days as ICEL went public, ISCO raised additional funding and BRTX grabbed more attention:
Top 10 Japanese Stocks To Watch Right Now: Ambit Biosciences Corp (AMBI)
Ambit Biosciences Corporation, incorporated on May 17, 2000, is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company�� lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company�� second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company�� third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.
Quizartinib
The Company�� lead drug candidate, quizartinib, is a once-daily, orally-administered, potent and selective inhibitor of FLT3, a validated target in the treatment of AML, and is in Phase IIb clinical development. The FLT3-ITD mutation acts like a power switch that causes leukemic cells, or blasts, to spread more aggressively and grow back more rapidly following chemotherapy, conferring an especially poor survival outcome. Quizartinib is designed to turn off this switch. The Company is developing a companion diagnostic test with Genoptix Medical Laboratory, a Novartis company, to identify FLT3-ITD positive patients.
AC410
The Company�� advanced drug candidate, AC410, is a potent, selective, orally-administered, small molecule inhibitor of JAK2, which has potential utility for the treatment of autoimmune and inflammatory diseases. Signaling through JAK controls the activation, proliferation and survival of various types of immune cells, and overactivation of such cells can exacerbate a range of normal inflammatory processes, resulting i! n inflammation. The Company�� initial JAK2 drug candidate, AC430, is a racemic mixture (50/50) of two enantiomers (mirror images), AC410 and AC409, and was studied in a Phase I clinical trial.
CSF1R Program
The Company is developing two potent and exquisitely selective small molecule compounds, AC708 and AC855 that both inhibit CSF1R and have potential utility in oncology, autoimmune and inflammatory diseases. Signaling through CSF1R controls the activation, proliferation and survival of macrophages, which are key mediators of immune system function and over-activation of macrophages, may result in exacerbation of certain diseases.
The Company competes with Abbvie Inc., Akinion Pharmaceuticals AB, Amgen Inc., ARIAD Pharmaceuticals, Inc., AROG Pharmaceuticals, LLC, ArQule, Inc., Astellas, AstraZeneca plc, Bayer AG, Celgene Corporation, Daiichi-Sankyo Company Limited, Galapagos NV, GlaxoSmithKline plc, Incyte Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Eli Lilly and Company, Novartis, Onyx Pharmaceuticals, Inc., Pfizer, Rigel Pharmaceuticals, Inc., F. Hoffman-LaRoche Ltd, and Vertex Pharmaceuticals Incorporated.
Advisors' Opinion:- [By Wallace Witkowski]
Ambit Biosciences Corp. (AMBI) �shares fell more than 37% to $8 in moderate volume. The small-cap biotech said it will not file an accelerated approval application with the Food and Drug Administration for its leukemia drug quizartinib after the agency disagreed with the company about the use of certain study data to support the drug�� efficacy.
Top 10 Japanese Stocks To Watch Right Now: Umpqua Holdings Corp (UMPQ)
Umpqua Holdings Corporation (Umpqua) is a financial holding company. Umpqua has two principal operating subsidiaries, Umpqua Bank (the Bank) and Umpqua Investments, Inc. (Umpqua Investments). The Bank is primarily engaged in the business of commercial and retail banking and the delivery of retail brokerage services. The Bank provides a range of banking, wealth management, mortgage banking and other financial services to corporate, institutional and individual customers. Umpqua Investments is a broker-dealer and investment advisor with offices in Portland, Lake Oswego, Medford, Oregon, and in many Umpqua Bank stores. Umpqua Investments offers a range of investment products and services, including stocks, fixed income securities (municipal, corporate, and government bonds, Certificate of Deposits (CDs), and money market instruments), mutual funds, annuities, options, retirement planning, money management services and life insurance. In December 2011, the Bank launched a commercial real estate division. In November 2012, the Company acquired Circle Bancorp, parent company of Circle Bank. In July 2013, Umpqua Holdings Corp completed its acquisition of Financial Pacific Holding Corp.
The Company offers a Switch Kit, which allows a customer to open a primary checking account with Umpqua Bank in less than 10 minutes. Other avenues, through which customers can access its products, include its Website equipped with an e-switchkit, which includes Internet banking through umpqua.online, mobile banking, and its 24-hour telephone voice response system. Umpqua Private Bank serves high net worth individuals with liquid investable assets by providing customized financial solutions and offerings. Umpqua private bank works collaboratively with the Bank�� affiliate retail brokerage Umpqua Investments and with the independent capital management firm Ferguson Wellman Capital Management. Umpqua Investments provides a range of brokerage services, including equity and fixed income products, mutual funds, annui! ties, options, retirement planning and money management services. Additionally, Umpqua Investments offers life insurance policies. At December 31, 2011, Umpqua Investments had 41Series seven-licensed financial advisors serving clients at three stand-alone retail brokerage offices and Investment Opportunity Centers located in many Bank stores.
Lending Activities
Umpqua offers loans for business and commercial customers, including accounts receivable and inventory financing, equipment loans, international trade, real estate construction loans and permanent financing and SBA program financing, as well as capital markets and treasury management. Additionally, it offers designed loan products for small businesses through its Small Business Lending Center. It also has a business banking division to increase lending to small and mid-sized businesses. The Company is also engaged in initiatives that continue to diversify the loan portfolio, including a focus on commercial and industrial loans in addition to financing owner-occupied properties.
Real estate loans are available for construction, purchase and refinancing of residential owner-occupied and rental properties. Borrowers can choose from a variety of fixed and adjustable rate options and terms. It sells residential real estate loans that originate into the secondary market. It also supports the Home Affordable Refinance Program and Home Affordable Modification Program. The Bank also provide loans to individual borrowers for a variety of purposes, including secured and unsecured personal loans, home equity and personal lines of credit and motor vehicle loans. The Bank makes both secured and unsecured loans to individuals and businesses. During 2011, its commercial real estate, commercial, residential, and consumer and other represented approximately 64%, 25%, 10%, and 1%, respectively, of the total non-covered loan and lease portfolio.
Source of Funds
The Company offers an array of deposit p! roducts, ! including non-interest-bearing checking accounts, interest-bearing checking and savings accounts, money market accounts and certificates of deposit. These accounts earn interest at rates established by management based on market factors. It also offers a seniors program to customers over fifty years old, which includes an array of banking services and other amenities, such as purchase discounts, vacation trips and seminars.
Investment Activities
As of December 31, 2011, Umpqua's portfolio of investments securities included securities issued by United States Treasury and agencies, and residential mortgage-backed securities and collateralized mortgage obligations. It also includes obligations of states and political subdivisions, other debt securities, and investments in mutual funds and other equity securities.
Advisors' Opinion:- [By Roberto Pedone]
Umpqua (UMPQ) is engaged in the business of commercial and retail banking and the delivery of retail brokerage services. This stock closed up 5% at $17.11 in Monday's trading session.
Monday's Volume: 2.16 million
Three-Month Average Volume: 686,781
Volume % Change: 235%From a technical perspective, UMPQ ripped sharply higher here right off its 50-day moving average of $16.51 with strong upside volume. This move is quickly pushing shares of UMPQ within range of triggering a big breakout trade. That trade will hit if UMPQ manages to take out Monday's intraday high of $17.46 and then once it clears its 52-week high at $17.48 with high volume.
Traders should now look for long-biased trades in UMPQ as long as it's trending above its 50-day at $16.51 or above more near-term support at $16 and then once it sustains a move or close above those breakout levels with volume that's near or above 686,781 shares. If that breakout hits soon, then UMPQ will set up to enter new 52-week-high territory above, which is bullish technical price action. Some possible upside targets off that breakout are $20 to $23.
Top 10 Japanese Stocks To Watch Right Now: Organovo Holdings Inc (ONVO)
Organovo Holdings, Inc. (Organovo), formerly Real Estate Restoration & Rental, Inc., incorporated in 2007, is a development-stage company. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. On December 28, 2011, Real Estate Restoration and Rental, Inc.�� (RERR) entered into an Agreement and Plan of Merger, pursuant to which RERR merged with its, wholly owned subsidiary, Organovo (Merger Sub). On February 8, 2012, the Company merged with and into Organovo Acquisition Corp. (Acquisition Corp.), a wholly owned subsidiary of Organovo, with the Company surviving the merger as a wholly owned subsidiary of Organovo Holdings (the Merger). As a result of the Merger, Organovo acquired the business of Organovo, Inc.
The Company has collaborative research agreements with Pfizer, Inc. (Pfizer) and United Therapeutic Corporation (Unither). As of March 31, 2012, it has five federal grants, including Small Business Innovation Research grants and developed the NovoGen MMX Bioprinter (its first-generation 3D bioprinter). The Company is engaged in the development of specific 3D human tissues to aid Pfizer in discovery of therapies in two areas of interest. In addition, in October 2011, it entered into a research agreement with Unither to establish and conduct a research program to discover treatments for pulmonary hypertension using its NovoGen MMX Bioprinter technology. Additionally, under the research agreement with Unither, the Company granted Unither an option to acquire from the Company a worldwide, royalty-bearing license in certain intellectual property created under the research agreement solely for use in the treatment or prevention of pulmonary hypertension and all other lung diseases.
The Company�� NovoGen MMX Bioprinter is an automate! d device that enables the fabrication of three-dimensional (3D) living tissues comprised of mammalian cells. A custom graphic user interface (GUI) facilitates the 3D design and execution of scripts that direct precision movement of the dispensing heads to deposit cellular building blocks (bio-ink) or supporting hydrogel. The Company is using a third party manufacturer, Invetech Pty., of Melbourne, Australia, to manufacture its NovoGen MMX Bioprinter. Its bioprinting technology and surrounding intellectual property and commercial rights serve as a platform for product generation across multiple markets that employ cell- and tissue-based products and services.
The Company competes with Organogenesis, Advanced BioHealing, Tengion, Genzyme, HumaCyte and Cytograft Tissue Engineering.
Advisors' Opinion:- [By Steve Symington]
To answer that question, remember what our fellow Fool Isaac Pino reminded us a few weeks ago:�high-end production 3-D printers from companies like 3D Systems, Stratasys (NASDAQ: SSYS ) , and ExOne (NASDAQ: XONE ) are capable of using dozens of materials to print infinitely more complicated items including shoes, saws, guitar bodies, and other functioning tools with moving parts.�Heck, 3-D bioprinting specialist�Organovo (NYSEMKT: ONVO ) is currently working feverishly on perfecting the process of designing and creating functional human tissue which -- putting inevitable regulatory hurdles for using the technology aside -- could obviously change the health care world as we know it.
- [By John Udovich]
As the the year comes to end, there is still a steady flow of interesting news coming from small cap biotech stocks like Organovo Holdings Inc (NYSEMKT: ONVO), Advanced Cell Technology, Inc (OTCMKTS: ACTC) and TNI BioTech (OTCMKTS: TNIB)�plus still largely private biotech companies like Genocea Biosciences (NASDAQ: GNCA), Retrophin (OTCMKTS: RTRX), Auspex Pharmaceuticals (NASDAQ: ASPX) and GlycoMimetics (NASDAQ: GLYC) who have filed to become the next potentially hot biotech IPOs���presumably some time early�next year. Just consider the following biotech news:
Top 10 Japanese Stocks To Watch Right Now: NEW GOLD INC.(NGD)
New Gold Inc. engages in the acquisition, exploration, extraction, processing, and reclamation of mineral properties. The company primarily explore for gold, silver, and copper deposits. Its operating properties include the Mesquite gold mine in the United States; the Cerro San Pedro gold-silver mine in Mexico; and the Peak gold-copper mine in Australia. The company also has development projects, including the New Afton gold, silver, and copper project in Canada; and a 30% interest in the El Morro copper-gold project in Chile. The company was formerly known as DRC Resources Corporation and changed its name to New Gold Inc. in June 2005. New Gold Inc. was founded in 1980 and is headquartered in Vancouver, Canada.
Advisors' Opinion:- [By Ben Levisohn]
Hamed singles out Goldcorp (GG) and Yamana Gold (AUY) as two companies that have strong production growth, falling costs, declining capital obligations and less debt than competitors. New Gold (NGD), meanwhile, should have the lowest all-on costs in the group at $731 an ounce, but its capital spending is likely to notes, Hamed says. Hamed rates Goldcorp and Yamana Overweight, while New Gold is rated Equal Weight.
- [By Ben Levisohn]
Bridges favorite stocks include Goldcorp, Newmont, Eldorado Gold (EGO) and New Gold (NGD).
Note, however, that these recommendations are all qualified in one way or another. Investors should keep that in mind before going all in on the gold miners.
- [By Ben Levisohn]
On an adjusted basis, Eldorado Gold (EGO) has the longest reserve/resource life amongst our coverage companies (39 years) with Goldcorp (GG) having the longest reserve/resource life (23 years) amongst the senior producers versus the group average of 22 years. Kinross Gold (KGC) and Iamgold (IAG) have the shortest adjusted reserve/resource lives amongst the senior and mid-tier producers (18 and 14 years respectively). On a percentage basis, the companies most affected by the adjustment are New Gold (NGD) and Iamgold which both saw reserve/resource lives fall by 47% however, we note that despite the adjustment,�New Gold still has the second longest reserve/resource life in our group (37 years). Newmont Mining was the least affected by the adjustments with reserve/resource life declining by only 12% to 22 years from 25 years.
Top 10 Japanese Stocks To Watch Right Now: Powershares Dynamic Pharmaceuticals Portfolio (PJP)
PowerShares Dynamic Pharmaceuticals Portfolio seeks investment results that correspond generally to the price and yield, before fees and expenses, of the Dynamic Pharmaceuticals Intellidex Index (the Pharmaceuticals Intellidex). The Fund will normally invest at least 80% of its total assets in common stocks of pharmaceutical companies. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Pharmaceuticals Intellidex. PowerShares Capital Management LLC (the Adviser) is the investment adviser for the Funds.
The Pharmaceuticals Intellidex comprises stocks of 30 United States-based pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. These companies may include, pharmaceutical companies and other companies involved in the research, development, manufacture, sale or distribution of drugs, including companies that facilitate the testing or regulatory approval of drugs.
Advisors' Opinion:- [By Jim Lowell]
Meanwhile, the PowerShares Dynamic Pharmaceuticals (PJP) has grabbed the top spot among sector ETFs.
The fund seeks investment results that correspond to the price and yield performance of the Dynamic Pharmaceuticals Intellidex Index, which is made up of 30 US companies involved in the research, development, production, sale, or distribution of pharmaceuticals and drugs.
- [By Gary Gordon]
On behalf of most of my clients in 2013, I chose to overweight tech and health care. However, I did so with areas that are traditionally less volatile. I continue to own Powershares Pharmaceuticals (PJP) and/or SPDR Select Healthcare (XLV). I’ve been a proponent of “old tech” with the attractive prices and dividends; First Trust NASDAQ Tech Dividend (TDIV) fits the bill. Additionally, I have remained faithful to iShares Small Cap Value (IJS) for small-cap exposure, rather than hop on the IWO express.
No comments:
Post a Comment